Faculty:

Gregg Stone, MD, Program Chair
Professor of Medicine
Director of Cardiovascular Research and Education Center for Interventional Vascular Therapy
Columbia University Medical Center
Vice-Chairman, The Cardiovascular Research Foundation
New York, NY

Stephen Ellis, MD
Cleveland Clinic Foundation
Cleveland, OH

Sigmund Silber, MD, FACC
Professor of Medicine
Cardiology Associates
Muller Hospital
Munich, Germany

Chuck Simonton, MD
Medical Director
Cardiovascular Research Division
Carolinas Heart Institute
Charlotte, NC

Agenda:

Introduction
Gregg Stone, MD

Overview of STENT Registry
Chuck Simonton, MD

Taxus V-In-Stent Restenosis Results
Stephen Ellis, MD

How to Critically Analyze Randomized Controlled Trials
Sigmund Silber, MD

Treatment of Patients with Complex Lesions
Gregg Stone, MD

Live Q&A
Following webcast and rebroadcasts

Target Audience:

This activity is designed for Cardiologists, Invasive Cardiovascular Nurses and Technologists, Cath Lab Administrators, Cardiology Fellows, and Pharmacists.

Learning Objectives:

Upon completion of this educational activity, participants should be able to:

• Evaluate registry results on the long-term efficacy and safety of different drug eluting stent platforms among real-world patients and clinical situations.
• Describe the latest drug eluting stent trial results in various complex cases
• Describe the risks and possible benefits of using drug eluting stents in complex lesions.
• Discuss the differences between single center vs multi center clinical trials.
• Apply the latest drug eluting stent clinical trial and registry results to your current and future patient caseload.
• Describe the indications for DES which have unequivocally shown to be safe and effective?
• Discuss new recently released clinical trial data to guide the appropriate usage of DES in complex patients and lesions
• Discuss the role of clinical registries in evaluating outcomes following coronary intervention
• Report the recent clinical outcomes of patients receiving drug eluting stents in the US from the STENT registry.

Accreditation:

MD/DO:
This activity is sponsored by the North American Center for Continuing Medical Education (NACCME). NACCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NACCME designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Each physician should claim only those credits that he/she actually spent in the educational activity.

This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies.

Pharmacists:
The North American Center for Continuing Medical Education (NACCME) is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. NACCME designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the American Council on Pharmaceutical Education. Universal Program Number 276-000-06-002-H04.

A statement of credit will be issued via US Mail within 8 weeks after successful completion of the activity post-test. A passing score of 70% is required for successful completion.

Nurses/ANCC:
North American Center for Continuing Medical Education is an approved provider of continuing nursing education by the Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. This continuing nursing education activity was approved by the PA State Nurses Association for 1.5 contact hours. Provider #: 110-3-E-03. Provider approved by the California Board of Registered Nursing, Provider Number 13255 for 1.5 contact hours.

Radiologic Technologists:
Activities approved by the American Medical Association (AMA PRA Category 1 Credit(s)™) are eligible for ARRT Category B credit as long as they are relevant to the radiologic sciences. Radiologic Technologists, registered by the ARRT, may claim up to 12 Category B credits per biennium.

Faculty Disclosures:

All faculty participating in Continuing Education programs sponsored by NACCME are expected to disclose to the meeting audience any real or apparent conflict(s) of interest related to the content of their presentation. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations. Full faculty disclosures will be made at the time of the meeting.

Commercial Supporter:

This activity is supported by an educational grant from Boston Scientific

Sponsor:

Sponsored by the North American Center for Continuing Medical Education (NACCME).